
|Articles|July 8, 2014
- Hematologic Malignancies
- Volume 1
- Issue 1
Resistance to Ibrutinib
Author(s)John C. Byrd, MD
John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses resistance to ibrutinib.
Advertisement
John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses resistance to ibrutinib.
View more about the treatment of chronic lymphocytic leukemia > >
Articles in this issue
over 11 years ago
In the Pipeline: Potential New Treatments for AMLover 11 years ago
Epidemiology in B-Cell Malignanciesover 11 years ago
Pathogenesis of Follicular Lymphomaover 11 years ago
IPI-145 and ABT-199 for Lymphoid Malignanciesover 11 years ago
BCL-2 Inhibitor Combo May Offer Remissions in CLLAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































